0.490
-0.02 (-2.99%)
| Penutupan Terdahulu | 0.505 |
| Buka | 0.505 |
| Jumlah Dagangan | 52,115 |
| Purata Dagangan (3B) | 2,059,440 |
| Modal Pasaran | 4,354,965 |
| Harga / Pendapatan (P/E Ke hadapan) | 1.43 |
| Harga / Jualan (P/S) | 6.02 |
| Harga / Buku (P/B) | 0.780 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 10 Apr 2025 |
| Margin Keuntungan | -102.80% |
| Margin Operasi (TTM) | -69.57% |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 382.00% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 914.75% |
| Nisbah Semasa (MRQ) | 0.540 |
| Aliran Tunai Operasi (OCF TTM) | -9.37 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -5.39 M |
| Pulangan Atas Aset (ROA TTM) | -37.28% |
| Pulangan Atas Ekuiti (ROE TTM) | -1,708.61% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - Specialty & Generic (US) | Bercampur | Bercampur |
| Drug Manufacturers - Specialty & Generic (Global) | Bercampur | Bercampur | |
| Stok | Redhill Biopharma Ltd. | - | - |
AISkor Stockmoo
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | -3.0 |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 1.0 |
| Osilator Teknikal | -4.0 |
| Penilaian Relatif | NA |
| Kesihatan Kewangan | -5.0 |
| AI Insight | NA |
| Purata | -1.45 |
|
RedHill Biopharma Ltd is a specialty biopharmaceutical company mainly focused on the U.S. development and commercialization of drugs for GI diseases, infectious diseases, and oncology. The Company is mainly focused on the advancement of its development pipeline of clinical-stage therapeutic candidates and also commercializes its GI-related product, Talicia (omeprazole, amoxicillin, and rifabutin) in the U.S. Its therapeutic candidates include opaganib, RHB-204, RHB-104, RHB-102 (Bekinda), and RHB-107. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - Specialty & Generic |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Institusi | 4.30% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Gagnon Securities Llc | 30 Jun 2026 | 88,405 |
| Lido Advisors, Llc | 30 Jun 2026 | 11,009 |
| Smartleaf Asset Management Llc | 30 Jun 2026 | 5 |
| Vermillion Wealth Management, Inc. | 30 Jun 2026 | 2 |
Tiada data dalam julat masa ini.
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| RADAY GILEAD | - | 0.480 | -14,310,000 | -6,868,800 |
| Jumlah Keseluruhan Kuantiti Bersih | -14,310,000 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -6,868,800 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 0.480 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| RADAY GILEAD | Pegawai | 01 Oct 2026 | Jual (-) | 14,310,000 | 0.480 | 6,868,800 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |